Literature DB >> 12443672

Calibrated serological techniques demonstrate significant different serum response rates to an oral killed cholera vaccine between Swedish and Nicaraguan children.

H O Hallander1, M Paniagua, F Espinoza, P Askelöf, E Corrales, M Ringman, J Storsaeter.   

Abstract

Serum responses to oral cholera vaccines were assessed in three paediatric vaccine trials, two in León, Nicaragua and one in Stockholm, Sweden. A calibrated anti-cholera toxin B subunit (CTB) IgA ELISA was used together with an assay for vibriocidal antibodies. Swedish children had lower pre-vaccination levels of antibody, but serum responses were more pronounced in Swedish children than in Nicaraguan children. Post-vaccination levels of anti-toxin antibody were generally above those found after natural infections with enterotoxigenic Escherichia coli, that cross-reacts serologically with Vibrio cholerae. Adverse events seen after vaccination were generally mild and of little clinical significance.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12443672     DOI: 10.1016/s0264-410x(02)00348-1

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  35 in total

1.  Memory B cell and other immune responses in children receiving two doses of an oral killed cholera vaccine compared to responses following natural cholera infection in Bangladesh.

Authors:  Daniel T Leung; Mohammad Arif Rahman; M Mohasin; Sweta M Patel; Amena Aktar; Farhana Khanam; Taher Uddin; M Asrafuzzaman Riyadh; Amit Saha; Mohammad Murshid Alam; Fahima Chowdhury; Ashraful Islam Khan; Richelle Charles; Regina LaRocque; Jason B Harris; Stephen B Calderwood; Firdausi Qadri; Edward T Ryan
Journal:  Clin Vaccine Immunol       Date:  2012-03-21

Review 2.  Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road.

Authors:  Myron M Levine; Karen L Kotloff; Eileen M Barry; Marcela F Pasetti; Marcelo B Sztein
Journal:  Nat Rev Microbiol       Date:  2007-07       Impact factor: 60.633

3.  Maternal Helminth Infection Is Associated With Higher Infant Immunoglobulin A Titers to Antigen in Orally Administered Vaccines.

Authors:  Carolyn E Clark; Michael P Fay; Martha E Chico; Carlos A Sandoval; Maritza G Vaca; Alexis Boyd; Philip J Cooper; Thomas B Nutman
Journal:  J Infect Dis       Date:  2016-02-16       Impact factor: 5.226

4.  Influence of gut microbiota on mucosal IgA antibody response to the polio vaccine.

Authors:  Ting Zhao; Jing Li; Yuting Fu; Hui Ye; Xiaochang Liu; Guoliang Li; Xiaolei Yang; Jingsi Yang
Journal:  NPJ Vaccines       Date:  2020-06-09       Impact factor: 7.344

Review 5.  Performance of rotavirus vaccines in developed and developing countries.

Authors:  Victoria Jiang; Baoming Jiang; Jacqueline Tate; Umesh D Parashar; Manish M Patel
Journal:  Hum Vaccin       Date:  2010-07

6.  Immune system development varies according to age, location, and anemia in African children.

Authors:  Danika L Hill; Edward J Carr; Tobias Rutishauser; Gemma Moncunill; Joseph J Campo; Silvia Innocentin; Maxmillian Mpina; Augusto Nhabomba; Anneth Tumbo; Chenjerai Jairoce; Henriëtte A Moll; Menno C van Zelm; Carlota Dobaño; Claudia Daubenberger; Michelle A Linterman
Journal:  Sci Transl Med       Date:  2020-02-05       Impact factor: 17.956

7.  Lactobacilli and Bifidobacteria enhance mucosal B cell responses and differentially modulate systemic antibody responses to an oral human rotavirus vaccine in a neonatal gnotobiotic pig disease model.

Authors:  Sukumar Kandasamy; Kuldeep S Chattha; Anastasia N Vlasova; Gireesh Rajashekara; Linda J Saif
Journal:  Gut Microbes       Date:  2014

8.  Pediatric small intestine bacterial overgrowth in low-income countries.

Authors:  Jeffrey R Donowitz; William A Petri
Journal:  Trends Mol Med       Date:  2014-11-15       Impact factor: 11.951

9.  Should the human microbiome be considered when developing vaccines?

Authors:  Rosana B R Ferreira; L Caetano M Antunes; B Brett Finlay
Journal:  PLoS Pathog       Date:  2010-11-18       Impact factor: 6.823

Review 10.  Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine.

Authors:  Myron M Levine
Journal:  BMC Biol       Date:  2010-10-04       Impact factor: 7.431

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.